SecBot SecBot
PRESS-RELEASE ·Filed Apr 8, 2026

MGNX

MacroGenics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

Resumption of enrollment removes a key regulatory overhang; traders should position ahead of the mid-2026 clinical update as next major catalyst. Watch for protocol refinement details and safety data in upcoming disclosures.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.44
T+0 close · Apr 8, 2026 · via day close
Latest settled
+32.85%
T+60 · $4.57
Vs SPY
+22.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $3.44entry
  2. T+1 · 7mo ago +4.65%α +4.71% · $3.60
  3. T+5 · 7mo ago −0.87%α −4.06% · $3.41
  4. T+20 · 6mo ago −12.50%α −20.07% · $3.01
  5. T+60 · 4mo ago +32.85%α +22.07% · $4.57
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab for gynecologic cancers, allowing resumption of new patient enrollment under a revised protocol. The company remains on track to provide a mid-2026 clinical update.

Key Facts

  • FDA lifted the partial clinical hold on the Phase 2 LINNET study of lorigerlimab.
  • Enrollment of new patients will resume with additional risk-mitigation measures for hematologic and cardiac toxicities.
  • Study evaluates lorigerlimab in platinum-resistant ovarian cancer and clear cell gynecologic cancer with an ORR primary endpoint.
  • 41 patients have already been dosed in the LINNET study; over 300 patients dosed across all lorigerlimab trials to date.
  • Mid-year 2026 update expected for the program.

Financial Impact

Non-dilutive near-term value catalyst; de-risks lorigerlimab development path

pipeline valueclinical progressregulatory risk

Risk Factors

  • Potential for renewed safety concerns given prior hematologic and cardiac toxicities.
  • Mid-2026 timeline for data readout implies limited near-term catalysts.
  • Market cap remains small ($213M), increasing volatility risk on future updates.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3270538

Track record

21 reports on MGNX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
  3. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
  4. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  5. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  6. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  7. Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  9. Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
  10. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 8, 2026